Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

NCT03024216 is registered in ClinicalTrials.gov with University of Hawaii as lead sponsor.

NCT NCT03024216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03024216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Lead sponsor
University of Hawaii
Phase
Phase 1
Overall status
Completed
Start date
February 6, 2017
Completion date
December 31, 2020
Enrollment
37 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic